Medullary thyroid cancer: Early detection and novel treatments

Current Opinion in Oncology

Volumn 21, Issue 1, 2009, Pages 5-10

  Roman, Sanziana ^a   Mehta, Pritesh ^b   Sosa, Julie Ann ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calcitonin screening; Medullary thyroid cancer; Novel chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CALCITONIN; FLUORODEOXYGLUCOSE F 18; PENTETATE INDIUM IN 111; UNCLASSIFIED DRUG; VANDETANIB; XL 184;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL; HUMAN; MEDULLARY THYROID CANCER; METASTASIS; MOLECULAR BIOLOGY; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SIPPLE SYNDROME; THYROID CANCER; THYROIDECTOMY; WHOLE BODY CT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCITONIN; CARCINOMA, MEDULLARY; FLUORODEOXYGLUCOSE F18; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 58149239805     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32831ba0b3     Document Type: Review

References (41)

1. Cheung KC, Roman SA, Wang TS, et al. Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis. J Clin Endocrinol Metab 2008; 93:2173-2180. This novel study analyzes the cost-effectiveness of routine basal calcitonin screening in the United States using a decision model for a hypothetical group of adult patients presenting for evaluation of thyroid nodules in the United States.
2. Hazard JB, Crile G Jr. Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. J Clin Endocrinol Metab 1959; 19:152-161.
3. Sippel J. The association of pheochromocytoma with carcinoma of the thyroid gland. Am J Med 1961; 31:163-166.
4. Williams E. Histogenesis of medullary carcinoma of the thyroid. J Clin Pathol 1966; 19:114-118.
5. Bergholm U, Telenius-Berg M, Johansson H, et al. Incidence of sporadic and familial medullary thyroid carcinoma in Sweden 1959 through 1981. A nationwide study in 126 patients. Acta Oncol 1990; 29:9-15.
6. Harach HR, Bergholm U. Medullary carcinoma of the thyroid with carcinoidlike features. J Clin Pathol 1993; 46:113-117.
7. Roman SA, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma. Cancer 2006; 107:2134-2142.
8. Fialkowski EA, Moley JF. Current approaches to medullary thyroid carcinoma, sporadic and familial. J Surg Oncol 2006; 94:737-747.
9. You YN, Lakhani V, Wells SA. New directions in the treatment of thyroid cancer. J Am Coll Surg 2007; 205 (4 Suppl 1):S45-S48.
10. Jimenez C, Min HU, Gagel RF. Management of medullary thyroid carcinoma. Endocrinol Metab Clin North Am 2008; 37:481-496.
11. Elisei R, Romei C, Cosci B, et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 2007; 92:4725-4729. This study assesses the role of RET genetic screening in identifying hereditary forms of medullary thyroid cancer frequently misdiagnosed as sporadic thyroid cancer.
12. Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003; 349:1517-1525.
13. Ball DW. Medullary thyroid cancer: monitoring and therapy. Endocrinol Metab Clin North Am 2007; 36:823-837.
14. Sippel RS, Kunnimalaiyaan M, Chen H. Current management of medullary thyroid cancer. Oncologist 2008; 13:539-547.
15. Castellone MD, Santoro M. Dysregulated RET signaling in thyroid cancer. Endocrinol Metab Clin North Am 2008; 37:363-374.
16. Gill JR, Reyes-Mugica M, lyengar S, et al. Early presentation of metastatic medullary carcinoma in multiple endocrine neoplasia, type HA: implications for therapy. J Pediatr 1996; 129:459-464.
17. Rodriguez Gonzalez JM, Balsalobre MD, Pomares F, et al. Prophylactic thyroidectomy in MEN 2A syndrome: experience in a single center. J Am Coll Surg 2002; 195:159-166.
18. Lombardo F, Baudin E, Chiefari E, et al. Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with ret mutation at codon 804. J Clin Endocrinol Metab 2002; 87:1674-1680.
19. Hofstra RMW, Landsvater RM, Ceccherini I, et al. A mutation in the RET protooncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994; 367:375-376.
20. Blaugrund JE, Johns MM, Eby YJ, et al. RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer. Hum Mol Genet 1994; 3:1895-1897.
21. Elisei R, Bottici V, Luchetti F, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10864 patients with nodular thyroid disorders. J Clin Endocrinol 2004; 89:163.
22. Wang TS, Ocal IT, Sosa JA, et al. Medullary thyroid carcinoma without marked elevation of calcitonin: A diagnostic and surveillance dilemma. Thyroid 2008; 18:889-894. This case report and review of literature presents a patient with calcitonin-negative MTC and discusses the methods of postoperative surveillance for this subset of patients.
23. Redding AH, Levine SN, Fowler MR. Normal preoperative calcitonin levels do not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses. Thyroid 2000; 10:919-922.
24. Bockhorn M, Frilling A, Rewerk S. Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma. Thyroid 2004; 14:468-470.
25. lacobone M, Niccoli-Sire P, Sebag F, et al. Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels. World J Surg 2002; 26:886-890.
26. Scheuba C, Kaserer K, Weinhausl A, et al. Is medullary thyroid cancer predictable? A prospective study of 86 patients with abnormal pentagastrin tests. Surgery (St Louis) 1999; 126:1089-1095.
27. Scheuba C, Kaserer K, Beiglmayer C, et al. Medullary thyroid microcarcinoma recommendations for treatment: a single-center experience. Surgery 2007; 142:1003-1010. This study interprets biochemical and pathohistological findings of patients with smMTC (≤10 mm) and makes recommendations regarding lymph node surgery in this subset of patients.
28. d'Herbomez M, Caron P, Bauters C, et al. Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smoking. Eur J Endocrinol 2007; 157:749.
29. Bugalho MJM, Santos JR, Sobrinho L. Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement. J Surg Oncol 2005; 91:56-60.
30. Hoff AO, Hoff PM. Medullary thyroid carcinoma. Hematol Oncol Clin North Am 2007; 21:475-488.
31. Hamy A, Pessaux P, Mirallie E, et al. Central neck dissection in the management of sporadic medullary thyroid microcarcinoma. Eur J Surg Oncol 2005; 31:774.
32. Machens A, Schneyer U, Holzhausen H-J, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 2005; 90:2029-2034.
33. Pelizzo MR, Boschin IM, Bemante P, et al. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol 2007; 33:493-497.
34. Machens A, Holzhausen H-J, Dralle H. Contralateral cervical and mediastinal lymph node metastasis in medullary thyroid cancer: systemic disease? Surgery 2006; 139:28-32.
35. Morton RP, Ahmad Z. Thyroid cancer invasion of neck structures: epidemiology, evaluation, staging and management. Curr Opin Otolaryngol Head Neck Surg 2007; 15:89-94.
36. Paulson EK, McDermott VG, Keogan MT, et al. Carcinoid metastases to the liver: role of triple-phase helical CT. Radiology 1998; 206:143-150.
37. 18F-FDG PET/CT performed with a hybrid tomography in detecting recurrent medullary thyroid carcinoma.
38. Ong SC, Schoder H, Patel SG, et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 2007; 48:501-507.
39. Giraudet AL, Vanel D, Leboulleux S, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 2007; 92:4185-4190.
40. Wells SA, Gosnell JE, Gagel RF, Moley JF, et al. Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial. J Clin Oncol 2007; 25:6018. This open-label phase II trial of vandetanib assesses the objective tumor response (RECIST criteria measured every 3 months), including disease control rate, biochemical response, safety, and tolerability.
41. Salgia R, Hong DS, Camacho LH, et al. A phase I dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies. J Clin Oncol 2007; 25 (18 Suppl):14031.